Education
About Us
Working with TipRanks
Follow Us
Invivyd (IVVD)
NASDAQ:IVVD
IVVD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.35 - $2.74
Previous CloseN/A
Volume606.77K
Average Volume (3M)4.96M
Market Cap
$377.36M
Enterprise Value$53.87M
Total Cash (Recent Filing)$34.91M
Total Debt (Recent Filing)$2.96M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Nov 12, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding214,409,450
10 Day Avg. Volume7,859,207
30 Day Avg. Volume4,960,906
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.14
Enterprise Value/Revenue1.17
Enterprise Value/Gross Profit1.25
Enterprise Value/Ebitda-0.49
Forecast
1Y Price Target
$7.50Price Target Upside326.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial StrengthA $57.5 million equity raise enhances Invivyd's runway to launch VYD2311 and advance its pipeline.
Product PotencyVYD2311 maintains ~17-fold improved potency versus PEMGARDA across dominant variants, supporting a broad prevention and treatment profile.
Regulatory ApprovalRegulatory clarity achieved with alignment on a single, randomized, placebo-controlled prevention trial for VYD2311, supporting a potential Biologics License Application.
Bears Say
Market CompetitionEmerging policy discussions suggest potential U.S. vaccine access changes that could favor long-acting prophylactic antibodies.
Operational ExpensesCommercial PEMGARDA uptake provides a bridge into respiratory season, with limited CMC spend for VYD2311 and disciplined operating expenses.
Revenue DependencePEMGARDA’s emergency use authorization business is seen as the foundation for near-term revenue and broader adoption of antibody prophylaxis.
Invivyd News
IVVD FAQ
What was Invivyd’s price range in the past 12 months?
Invivyd lowest stock price was $0.35 and its highest was $2.74 in the past 12 months.
What is Invivyd’s market cap?
Invivyd’s market cap is $377.36M.
When is Invivyd’s upcoming earnings report date?
Invivyd’s upcoming earnings report date is Nov 12, 2025 which is in 29 days.
How were Invivyd’s earnings last quarter?
Invivyd released its earnings results on Aug 14, 2025. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.004 by -$0.116.
Is Invivyd overvalued?
According to Wall Street analysts Invivyd’s price is currently Undervalued.
Does Invivyd pay dividends?
Invivyd does not currently pay dividends.
What is Invivyd’s EPS estimate?
Invivyd’s EPS estimate is -0.09.
How many shares outstanding does Invivyd have?
Invivyd has 214,409,450 shares outstanding.
What happened to Invivyd’s price movement after its last earnings report?
Invivyd reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.004. Following the earnings report the stock price went down -11.25%.
Which hedge fund is a major shareholder of Invivyd?
Currently, no hedge funds are holding shares in IVVD
Invivyd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.50 (326.14% Upside)
$7.50 (326.14% Upside)
Blogger Sentiment
Bullish
IVVD Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 14.2%
Last 30 Days ▲ 14.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
94.69%
12-Months-Change
Fundamentals
Return on Equity
-120.08%
Trailing 12-Months
Asset Growth
-49.74%
Trailing 12-Months
Company Description
Invivyd
Invivyd, Inc. (IVVD) is a biotechnology company that focuses on the discovery, development, and commercialization of innovative therapies for infectious diseases. The company's core products include monoclonal antibodies designed to treat and prevent viral infections, with a particular emphasis on addressing unmet medical needs in the field of infectious disease prevention and treatment.
IVVD Company Deck
IVVD Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a strategic shift towards internalization and pipeline expansion, with promising early indicators and additional capital access. However, challenges with Q1 revenue and regulatory hurdles for EUA expansion tempered the outlook.View all IVVD earnings summariesIVVD Stock 12 Month Forecast
Average Price Target
$7.50
▲(326.14% Upside)
Technical Analysis
VistaGen Therapeutics
―
vTv Therapeutics
―
Clearside Biomedical
―
Jasper Therapeutics
―
Inozyme Pharma
―
Ownership Overview
14.15% Insiders
3.14% Mutual Funds
24.29% Other Institutional Investors
56.27% Public Companies and
Individual Investors